Cosmos Health Launches New Nanotechnology Research Initiative to Create Advanced Nutraceutical Formulas with Improved Phytochemical Effectiveness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Should l Buy COSM?
Source: Newsfilter
New R&D Program: Cosmos Health Inc. has launched a research and development initiative utilizing nanotechnology to enhance the effectiveness of phytochemical constituents in dietary supplements, building on their CCX Hydrogel platform.
Sustainable Innovation: The company emphasizes a sustainable, solvent-free process for creating plant-based extract-loaded phytosomes, aligning with its commitment to environmentally responsible manufacturing and nutraceutical applications.
CEO and R&D Insights: CEO Greg Siokas highlighted the potential of combining nanotechnology with advanced phytochemical formulations to create next-generation dietary supplements, while Dr. Panagiotis Zoumpoulakis noted the benefits of nanoscale engineering for optimizing bioactive compound absorption.
Company Overview: Cosmos Health Inc. is a diversified global healthcare group with a portfolio of pharmaceutical and nutraceutical brands, focusing on R&D partnerships for major health disorders and expanding its distribution across Europe, Asia, and North America.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
See More
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
MIMARU Launches Clothing-Sharing Service to Lessen Luggage Burden
- Service Innovation: MIMARU partners with Sumitomo Corporation to launch the 'Any Wear, Anywhere' clothing-sharing service, set to debut on January 19, 2026, aimed at providing family travelers with a lighter travel option, which is expected to enhance customer satisfaction and attract more family bookings.
- Booking Convenience: The service allows guests to reserve climate-appropriate outfits online before departure, reducing the need to carry bulky clothing, thereby enhancing travel convenience and sustainability, aligning with modern family travel needs.
- Market Positioning: MIMARU targets international families, with over 90% of guests coming from abroad, and the introduction of this service will further solidify its leadership in the family-friendly accommodation market, likely driving future business growth.
- Positive Customer Feedback: Early feedback from customers indicates that renting winter clothing is more cost-effective than purchasing, and lighter luggage allows for more shopping space, suggesting that the service has significant potential in enhancing customer experience.
See More
Cosmos Health Partners with Prime Ledger to Manage $300M Treasury and Tokenize IP
- Strategic Partnership: Cosmos Health has entered a long-term strategic partnership with Prime Ledger to digitally transform its financial operations, particularly managing a $300 million treasury, thereby enhancing efficiency and reducing risk in treasury management.
- Asset Tokenization: A cornerstone of this collaboration is the tokenization of Cosmos Health's high-value intellectual property, with Prime Ledger designing a token issuance platform that will unlock new capitalization channels and drive innovation and growth.
- Data Infrastructure Integration: The partnership also includes integrating Cosmos Health's data infrastructure using Prime Ledger's relationship with Conduit Network, which will optimize on-chain and off-chain data management, enhancing financial reporting and compliance capabilities.
- Project Commencement: The initial phase of this engagement is set to begin in Q4 2025, focusing on strategic planning and platform design, marking a significant advancement for Cosmos Health in the digital economy.
See More
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
See More
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
MIMARU Launches Clothing-Sharing Service to Lessen Luggage Burden
- Service Innovation: MIMARU partners with Sumitomo Corporation to launch the 'Any Wear, Anywhere' clothing-sharing service, set to debut on January 19, 2026, aimed at providing family travelers with a lighter travel option, which is expected to enhance customer satisfaction and attract more family bookings.
- Booking Convenience: The service allows guests to reserve climate-appropriate outfits online before departure, reducing the need to carry bulky clothing, thereby enhancing travel convenience and sustainability, aligning with modern family travel needs.
- Market Positioning: MIMARU targets international families, with over 90% of guests coming from abroad, and the introduction of this service will further solidify its leadership in the family-friendly accommodation market, likely driving future business growth.
- Positive Customer Feedback: Early feedback from customers indicates that renting winter clothing is more cost-effective than purchasing, and lighter luggage allows for more shopping space, suggesting that the service has significant potential in enhancing customer experience.
See More
Cosmos Health Partners with Prime Ledger to Manage $300M Treasury and Tokenize IP
- Strategic Partnership: Cosmos Health has entered a long-term strategic partnership with Prime Ledger to digitally transform its financial operations, particularly managing a $300 million treasury, thereby enhancing efficiency and reducing risk in treasury management.
- Asset Tokenization: A cornerstone of this collaboration is the tokenization of Cosmos Health's high-value intellectual property, with Prime Ledger designing a token issuance platform that will unlock new capitalization channels and drive innovation and growth.
- Data Infrastructure Integration: The partnership also includes integrating Cosmos Health's data infrastructure using Prime Ledger's relationship with Conduit Network, which will optimize on-chain and off-chain data management, enhancing financial reporting and compliance capabilities.
- Project Commencement: The initial phase of this engagement is set to begin in Q4 2025, focusing on strategic planning and platform design, marking a significant advancement for Cosmos Health in the digital economy.
See More
